Pharmaceutical acquisition and mergers of 2025
The year 2025 marked a strong revival in pharmaceutical mergers and acquisitions, as global drug makers moved firmly to strengthen pipelines, manage upcoming patent expiries, and secure sustainable growth. Several high-value and strategically important deals defined the year, reflecting renewed confidence in the sector. Major pharmaceutical companies pursued acquisitions not just for scale, but for access to late-stage assets, innovative technologies, and high-growth therapeutic areas.


Vinay Kumar Singh. 







